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AbsTrACT
study design Pilot, multicentre randomised clinical trial 
(RCT).
Objectives Assess viability of performing a definitive 
RCT and compare preliminary effects of movement pattern 
training (MoveTrain) and strengthening/flexibility (Standard) 
to improve function in people with chronic hip- related 
groin pain (HRGP).
background To determine the best physical therapist- 
led intervention for patients with HRGP, we must 
understand treatment effects of different treatment 
modes.
Methods Forty- six patients (17M:29F; 29±5.3 years; 
body mass index 25.6±6.3 kg/m2) with HRGP were 
randomised. MoveTrain included task- specific training 
to optimise biomechanics during daily tasks. Standard 
included strengthening/flexibility. Treatment included 10 
visits/12 weeks and home exercise programme (HEP). 
Primary outcomes for feasibility were recruitment, 
retention, treatment adherence and treatment fidelity. 
Secondary outcomes were patient- reported function (Hip 
disability and Osteoarthritis Outcome Score (HOOS)), lower 
extremity kinematics and hip muscle strength.
results We achieved target recruitment, and retention 
was excellent (91%). Patient session attendance was high 
(93%); however, reported HEP adherence (62%) was lower 
than expected. Physical therapists’ adherence to treatment 
protocols was high (90%). Patients demonstrated high 
treatment receipt; 91% of exercises performed were 
rated independent. Both groups demonstrated clinically 
important improvements in function (HOOS) and muscle 
strength; however, there were no between- group 
differences (HOOS subscales, p≥0.13, strength, p≥0.34). 
Compared with Standard, MoveTrain demonstrated greater 
reductions in hip adduction (p=0.016) and pelvic drop 
(p=0.026) during a single leg squat. No adverse events 
were noted.
Conclusion Our experience in completing this RCT 
confirmed that a larger, multicentre RCT is feasible and 
highlighted modifications we will implement to optimise 
the future RCT.
Trial registration number NCT02913222.
InTrOduCTIOn
Hip- related groin pain (HRGP) results in 
significant pain and activity limitations among 
young to middle aged adults. Hip disorders 
proposed to contribute to HRGP include 
femoroacetabular impingement syndrome 
(FAIS), acetabular dysplasia, labral tears 
and injury to other intra- articular structures. 
Additionally, acetabular dysplasia and FAIS 
are associated with development of hip osteo-
arthritis.1 2 It is important to intervene early 
and provide effective treatment to improve 
pain and function among those with HRGP 
and potentially prevent or delay hip osteoar-
thritis (OA).
While significant literature exists related 
to surgical interventions, evidence related 
to physical therapist (PT)- led intervention 
remains sparse.3–5 Three randomised clin-
ical trials (RCTs) were recently published 
comparing arthroscopic surgery to PT- led 
intervention for patients with FAIS. Two 
studies6 7 reported greater improvement 
among those who received surgery compared 
What are the new findings
 ► Using our methods, a large, multicentre randomised 
clinical trial (RCT) to compare MoveTrain and 
Standard treatment for patients with hip- related 
groin pain (HRGP) is feasible as demonstrated by 
high retention, patient adherence and treatment 
fidelity.
 ► Preliminary findings related to patient- reported out-
comes, kinematics and strength suggest that reha-
bilitation may be appropriate for patients with HRGP; 
however, further study is needed.
 ► A better understanding of treatment effects of re-
habilitation will allow us to better compare surgical 
and non- surgical treatments, thus ultimately leading 
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with PT- led intervention, but one study reported no 
differences between the two interventions.8 These mixed 
findings may be partially due to limited evidence avail-
able to inform PT- led intervention. PT- led interventions 
described in previous RCTs were based primarily on 
expert opinion, resulting in intervention that is multi-
modal and non- standard, thus limiting our ability to 
make conclusions about the effect of any one treatment. 
To ultimately determine comparative effectiveness of 
PT- led intervention and surgical intervention of HRGP, 
we must first determine the best PT- led intervention by 
understanding the effects of different treatments. We 
compared two PT- led interventions, movement pattern 
training (MoveTrain) and traditional strengthening and 
flexibility (Standard).
The goal of MoveTrain is to reduce hip joint stress by 
optimising biomechanics during functional tasks. The 
key element of MoveTrain is task- specific instruction to 
correct abnormal movement patterns during daily activi-
ties. In our previous proof- of- concept study, we noted that 
patients with HRGP who participated in MoveTrain were 
able to reduce hip adduction motion during a single leg 
squat,9 and this reduction was associated with improved 
patient- reported function.9 10 Given resources required 
to conduct a larger RCT to definitively determine Move-
Train effects, we designed a pilot, multicentre RCT to 
assess the viability of performing a definitive RCT.
The primary purpose of this study was to determine 
patient retention and treatment adherence and to demon-
strate treatment fidelity among treatment providers and 
patients at both clinical sites. Our secondary purpose 
was to compare the preliminary effects of MoveTrain to 
Standard on patient- reported function, lower extremity 
kinematics (targeted by MoveTrain) and hip muscle 
strength (targeted by Standard).
MeThOds
study design, setting and patient involvement
This study was a pilot, multicentre RCT (figure 1). Data 
collection and treatment occurred at The Movement 
Science Research Center at Washington University’s 
Program in Physical Therapy and The Physical Therapy 
– Clinical and Translational Research Center at the 
University of Pittsburgh. Washington University served 
as the coordinating centre and single site institutional 
review board (IRB). This study was approved by Human 
Research Protection Offices of Washington Univer-
sity and University of Pittsburgh. All patients signed 
an informed consent statement prior to participating. 
Patients were not involved in the design, recruitment or 
conduct of the study.
Manual of operations (MOP) development and training
An MOP was developed to document standard methods 
for all study components. To optimise treatment fidelity, 
we used the treatment fidelity framework developed 
by National Institutes of Health’s Behavioral Change 
Consortium.11 12 Active ingredients believed to affect 
patient outcomes for each treatment arm were identified 
and operationally defined. Each treatment protocol was 
reviewed by experts at both sites to ensure it reflected 
the underlying theory of its respective approach. The 
first author led onsite training for examiners (n=2) and 
treating PTs (n=5); all were PTs with 6–27 years of expe-
rience. Training included review and discussion of the 
MOP, patient scenario role plays to demonstrate assess-
ment and treatment concepts and discussion to identify 
barriers to study protocol performance and patient treat-
ment adherence. Training time totalled 16 hours per site.
Participants
Patients were recruited between January 2017 and 
February 2018, from healthcare clinics; research 
volunteer databases; social media; and other written 
communications. To be eligible, patients had to be 15–40 
years old; report deep hip joint or anterior groin pain 
that was reproduced with flexion, adduction, internal 
rotation impingement test13; report pain ≥3/10 and 
present ≥3 months; and demonstrate functional limita-
tion with modified Harris Hip Score14 <90. Exclusion 
criteria included previous hip surgery, fracture, infec-
tion or pain due to high impact trauma; diagnosed with 
Legg- Calve- Perthes disease or slipped capital femoral 
epiphysis; inflammatory disease; neurological involve-
ment affecting balance; pain, numbness or tingling that 
radiates into thigh; pregnancy; and screening tests indi-
cating hip pain was referred from the spine.
Assessment (baseline and post-treatment)
Patients who passed initial screening were scheduled for 
clinical examination, which included assessment of final 
screening criteria and, if the patient was determined to 
be eligible, baseline assessment. Patients completed self- 
report questionnaires and participated in assessment of 
movement patterns and hip strength. Patients were then 
randomised into MoveTrain or Standard. Thirteen weeks 
after enrolment, patients returned for post- treatment 
testing.
Treatments
Treatments were delivered according to the Template 
for intervention Description and Replication Guide-
lines.15 Treatment for both groups included 10 
supervised sessions over 12 weeks and daily home exer-
cise programme (HEP). Both treatment arms included 
assessment of patient goals, patient education and HEP 
instruction. Patient education focused on patient- specific 
tasks, which were identified using the Patient Specific 
Functional Scale (PSFS).16 A brief description of each 
treatment arm is provided below.
Movement pattern training (MoveTrain) (online 
supplementary appendix A): treatment focus was on task- 
specific training to improve lower extremity kinematics 
during functional and patient- specific tasks. Patient 
education included instruction in abnormal movement 
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Figure 1 Study flow diagram. CONSORT flow diagram adapted. CONSORT, Consolidated Standards of Reporting Trials; WU, 
Washington University; UP, University of Pittsburgh. *inclusion criteria categories are not mutually exclusive.
during each task. Exercises included repeated practice 
of tasks using optimised movement patterns. Verbal cues 
and visual aids were used to assist the patient. Based on 
patient performance, task difficulty was progressed by 
varying repetitions performed, increasing load or speed 
or changing support surface.
Standard rehabilitation (Standard) (online supplemen-
tary appendix B): treatment focus was on progressive lower 
extremity and trunk strengthening and lower extremity 
flexibility. Patient education included instruction to 
modify intensity, frequency or duration of patient- specific 
tasks. Strengthening and flexibility exercises prescribed 
were selected using current clinical practice guidelines17 
and previous reports.5 18 Each patient was progressed by 
increasing repetitions performed or increasing load.
Primary outcomes: feasibility
Primary outcomes were related to feasibility of the larger 
trial. Recruitment rate was defined as the number of 
patients deemed eligible who agreed to participation. 
Retention rate was defined as the percentage of those 
who completed post- treatment testing. Patient treat-
ment session adherence was defined as the percentage 
of supervised visits attended. Patient HEP adherence was 
defined as the percentage of days the patient reported 
completing their HEP.
To assess treatment fidelity,11 12 we assessed PT treat-
ment delivery and patient treatment receipt. Treatment 
delivery was assessed using prestudy assessment and 
poststudy chart reviews to assess protocol adherence. 
Prestudy assessment included a written exam and role- 
played scenarios.19 For role- played scenarios, a checklist 
was used to document standard performance of active 
ingredients for each treatment. To assess protocol adher-
ence, a PT who was not involved in providing treatment 
completed chart reviews. A standard form was used to 
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Figure 2 (A) Initial position. Line A is drawn between the anterior superior iliac spine (ASIS) markers and is the initial position 
of the pelvis. Line B is drawn from the sternal marker to the midpoint of line A and is the initial position of the trunk. (B) Final 
depth of squat. Line C is drawn between the ASIS markers and is the final position of the pelvis. Line D is drawn from the 
sternal marker to the midpoint of line C and is the final position of the trunk. Line E is drawn from the ASIS marker to the femur 
marker on the weight- bearing leg and is the final position of the femur. (C) Angle measurement. Hip adduction angle is defined 
by lines C and E. Positive values indicate hip adduction; pelvic excursion is defined by lines A and C. Negative values indicate 
a pelvic tilt in which the non- weight- bearing side is lowering; trunk excursion is defined by lines B and D. Positive values 
indicate the trunk is leaning towards the weightbearing limb.
treatment arm was documented. Protocol adherence was 
scored as percentage of active ingredients completed.
In addition to our a prior feasibility outcomes, we 
assessed patient treatment receipt, which relates to 
ability to understand key treatment concepts, and ability 
to independently perform tasks.11 12 Using our previously 
published methods,19 treatment receipt was scored by 
the treating PT as the proportion of exercises the patient 
performed independently.
secondary outcomes: preliminary effectiveness
Preliminary effectiveness outcomes determined a priori 
were the Hip dysfunction and Osteoarthritis Outcome 
Score (HOOS) subscales of activities of daily living (ADL) 
and symptoms,20 hip adduction angle during a single leg 
squat and hip muscle strength.
Patient-reported outcome measures
The HOOS is a reliable21–23 and valid21 23 hip- specific 
patient- reported outcome used to quantify activity limita-
tions among those with hip disorders. The values for 
the HOOS subscales, including pain, symptoms, ADLs, 
sport and recreation (Sport) and quality of life range 
from 0 to 100 with higher scores indicating higher levels 
physical function. The established values for minimum 
important change (MIC) for people with HRGP who 
have undergone arthroscopic surgery are 8, 9, 9, 6, 10 
and 11, respectively.23 Values for MIC for non- surgical 
management are not available. In addition, we collected 
PSFS16; Patient- Reported Outcomes Measurement Infor-
mation System (PROMIS) Scores24 25; and Pain Numeric 
Rating Scale.26 Information for the additional measures 
are provided in table 4.
Kinematics
A digital camera was used to capture two- dimensional 
motion while the patient completed three single leg 
squats.27 figure 2 demonstrates the variables of interest 
including hip adduction, pelvic tilt (obliquity/drop) 
and trunk lean (ipsilateral lean). Values of three trials 
were averaged for each variable. Inter- rater reliability of 
all measures among our group was excellent (intraclass 
correlation (ICC
3,3:
) >0.98, SE of measurements <1°).
Muscle strength
A microFET3 hand- held dynamometer (Hogan Health 
Industries, Salt Lake City, Utah, USA) was used to assess 
hip muscle strength of hip external rotators, internal 
rotators, abductors, adductors, flexors and extensors. 
Make tests28 were used, incorporating a strap for resis-
tance. After a practice trial, three maximal trials were 
performed. Force values of three trials were averaged and 
used to calculate torque, then normalised by weight and 
height.29 Strength was not a primary outcome, and this 
study was funded by an R21 mechanism, which provides 
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study of each secondary outcome was simply not feasible 
within this mechanism. A previous study using similar 
methods reported high test–retest reliability, ICCs >0.82.
A priori criteria for success
A priori criteria for success included: (1) 46 partici-
pants recruited; (2) 90% retention9; (3) 90% adherence 
to attending treatment sessions; (4) 80% adherence to 
HEP; and (5) treatment providers scoring at least 95% 
on prestudy examination and 80% protocol adherence.
We hypothesised MoveTrain would demonstrate 
greater improvement in HOOS and greater reduction 
in peak hip adduction during functional tasks compared 
with Standard, despite possibly demonstrating less hip 
strength.
Pilot trial sample size
Sample size for primary outcomes was based on preci-
sion and assumed that observed rates of adherence and 
retention would be at least 90%.9 With a sample size of 
46 (23/group), 95% CI around observed rates of adher-
ence and retention were expected to be 78%–96% (ie, 
within 9% of the true rate). The study was designed to 
estimate effect sizes for treatment outcomes; therefore, 
the study was 80% powered to detect large effect sizes of 
0.9 or above.
randomisation
Patients were randomised to treatment in 1:1 ratio 
stratified by site, sex and HOOSSymptoms subgroup 
(determined from median split of preliminary data). 
Within each stratum, patients were allocated using a 
variable block size. Randomisation sequences were 
generated a priori using a formal probability model and 
were elicited from the data capture system. Given the 
nature of treatment, it was not possible to blind treating 
PTs or patients to treatment assignment. Study personnel 
performing assessments and kinematic measurements 
were blinded to group.
statistical analysis
Fisher’s exact test compared retention and patient adher-
ence to treatment session rates by site and by group. 
Patient adherence to HEP, therapists’ treatment delivery 
and patient treatment receipt were compared by site and 
group using Wilcoxon’s test.
Data collected at pretest and post- test were analysed 
with analysis of covariance where post- test was the depen-
dent variable, pretest was the covariate and treatment 
group was the independent variable that tests the null 
hypothesis that after adjusting for pretest, post- test is not 
significantly different across treatment groups. A general 
linear model was used when residuals were normally 
distributed, and homogeneity of regression lines assump-
tion was satisfied, otherwise non- parametric covariance 
analysis30 was used. Multinomial generalised estimating 




Table 1 provides baseline characteristics of study groups. 
Overall results related to study feasibility along with site- 
specific and treatment group- specific comparisons are 
provided in table 2.
Recruitment and Retention Rate
A flow diagram of patient recruitment and retention are 
provided in figure 1. Overall, 42/46 (91%; 95% CI 83% 
to 99%) of patients completed post- treatment testing 
(table 2).
Treatment adherence
Overall, 43/46 (93%; 95% CI 86% to 100%) of patients 
attended at least 90% of their sessions. The 43 patients 
who completed at least 90% of supervised sessions 
reported HEP completion on 62% (range 9%–97%) of 
days.
PTs’ treatment delivery
All providers scored >95% on written exam and role- 
played scenarios. Chart reviews resulted in data for 
132 treatment visits for the 45 patients who completed 
at least one treatment visit. Overall, the proportion of 
active ingredients completed by PTs was 90% (range 
60%–100%).
Patients’ treatment receipt
Overall, the proportion of exercises rated independent 
was 91% (range 18%–100%).
Protocol deviations
We had nine protocol deviations. Two patients had 
their baseline HOOSSymptom score entered into the 
data system incorrectly, resulting in each patient being 
randomised to treatment within an incorrect stratum. Due 
to personal scheduling issues, four patients completed 
post- treatment examination before 13 weeks and three 
completed post- treatment examination after 16 weeks.
Safety
No unexpected adverse events were noted. Twenty- seven 
patients reported discomfort in hip, knee or spine with 
performance of at least one exercise (table 3). More 
patients in Standard reported pain with at least one exer-
cise compared with MoveTrain (85% vs 45%, respectively 
p=0.008). Each reported exercise was modified by the 
treating PT.
secondary outcomes: preliminary effectiveness
Both groups demonstrated improvements in all HOOS 
subscales; however, there were no between- group 
differences (table 4). Both groups also demonstrated 
similar improvements in PSFS, PROMIS scores and 
Pain Numeric Rating scales. MoveTrain demonstrated 
a greater reduction in hip adduction and pelvic tilt 
(drop) during the single leg squat compared with 
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Gender, n (%)         
  Male 17 (37) 17 (40) 9 (41) 8 (40)
  Female 29 (63) 25 (60) 13 (59) 12 (60)
Race, n (%)         
  American Indian or Alaska Native, 
White
1 (2) 1 (2) 1 (5) 0 (0)
  Asian 1 (2) 1 (2) 1 (5) 0 (0)
  Asian, White 1 (2%) 1 (2) 1 (5) 0 (0)
  Black or African- American 4 (9) 4 (10% 4 (18) 0 (0)
  White 39 (85) 35 (83) 15 (68) 20 (100)
Ethnicity, n (%)
Hispanic or Latino   0 (0)   0 (0)   0 (0)   0 (0)
Not Hispanic or Latino 46 (100) 42 (100) 22 (100) 20 (100)
Education, n (%)         
  9th–11th grade 1 (2) 1 (2) 1 (5) 0 (0)
  12th grade 1 (2) 1 (2) 0 (0) 1 (5)
  Some college/associate degree 5 (11) 3 (7) 3 (14) 0 (0)
  College degree 26 (57) 25 (60) 13 (59) 12 (60)
  Non- doctoral graduate degree 9 (20) 8 (19) 4 (18) 4 (20)
  Doctoral degree 4 (9) 4 (10) 1 (5) 3 (15)
Study limb, n (%)         
  Left 21 (46) 19 (45) 10 (45) 9 (45)
  Right 25 (54) 23 (55) 12 (55) 11 (55)
Pain: involved side, n (%)         
  Left 15 (33) 13 (31) 8 (36) 5 (25)
  Right 15 (33) 13 (31) 6 (27) 7 (35)
  Bilateral 16 (35) 16 (38) 8 (36) 8 (40)














        








  Average pain† 3 (1–9) 3 (1–9) 4 (1–9) 3 (1–8)
  Worst pain† 6 (2–10) 6 (2–10) 6 (2–9) 5.5 (3–10)
*Patients are asked to rate their activity level over the previous 6 months. 10=regularly participates in impact sports; 1=wholly inactive, 
dependent on others.
†Pain rated by patients using a verbal numerical pain rating scale. 0=no pain; 10=worst pain imaginable.
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Retention rate, n (%)* 42 (91) 30 (100) 12 (75) 0.01† 22 (96) 20 (87) 0.61†
Patient adherent to treatment 
session attendance, n (%)‡
















































Active ingredients for treatment 












*Retention rate is defined as the percentage of those enrolled at baseline who completed testing after treatment.
†Fisher’s exact test for group comparison.
‡Treatment session attendance was documented by the physical therapist. The variable for treatment session attendance is the number of patients who attended 
at least 90% (9 of 10) of their sessions.
§Number of patients completing at least nine supervised visits.
¶HEP adherence: participants were instructed to perform their HEP one time per day. The variable for HEP adherence was calculated as the total number of days 
reported by the participant to have completed the prescribed exercises, summed over the entire treatment period and divided by the total number of treatment 
days.
**Wilcoxon’s test.
††The total number of exercises the physical therapist reviewed and the total number of those exercises they rated as independent were each summed across all 
treatment visits to derive the per cent of exercises rated as independent across the entire treatment (Σ independent / Σ reviewed * 100).
‡‡Number of patients who completed at least one supervised treatment visit.
§§Treatment delivery assessed using chart reviews to determine if the active ingredients of the treatment was provided. The variable for treatment delivery is the 
proportion of active ingredients completed and documented by the treatment physical therapists for 132 treatment visits.
HEP, home exercise programme; MoveTrain, movement pattern training group.
Table 3 The number of patients who reported pain or 
discomfort with at least one exercise during treatment
Variable* MoveTrain Standard Total
Hip 7 13 20
Knee 1 1
Lumbar spine 1 1
Hip and lumbar spine 1 1
Hip and knee 1 3 4
Total 10 17 27
Exercises were modified by the treating physical therapist.
*Each number represents one participant.
MoveTrain, movement pattern training group.
increases in strength after treatment ranging from 6% 
to 16% (table 5).
dIsCussIOn
We have established feasibility of completing a large, 
multicentre RCT to compare effectiveness of MoveTrain 
to Standard. We met our target enrolment and retention 
rate. Patient adherence to treatment session attendance 
was high. however, patient- reported adherence to HEP 
was lower than expected. Regarding treatment fidelity, 
we demonstrated high rates of treatment delivery among 
PTs and treatment receipt among patients. Our prelimi-
nary results related to secondary outcomes suggest both 
MoveTrain and Standard resulted in clinically signifi-
cant improvements in patient- reported outcomes and 
hip muscle strength; however, only those in MoveTrain 
showed improvement in kinematics.
Feasibility
We were able to meet our recruitment goals within 
13 months of initiating recruitment. This suggests 
our recruitment methods would result in an esti-
mated 177 patients for a 5- year project. Our retention 
rate for post- treatment testing was 91%, higher than 
the 80% follow- up required for a high- quality RCT.31 
We provided compensation for testing sessions and 
treatment free of charge, which may have increased 
retention. Additionally, there was frequent contact 
between study personnel and patients, including weekly 
treatment sessions and multiple communications with 
research coordinators.
Treatment session attendance was high, indicating 
feasibility of weekly supervised sessions. Patient self- 
reported HEP adherence was lower than hypothesised. 
Based on informal discussions and written commu-
nications, patients reported difficulty completing all 
exercises every day and suggested the HEP be modi-
fied. Despite lower than expected HEP adherence, 
patients in both groups demonstrated improvements in 
HOOS and treatment- targeted mechanism, kinematics 
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Mean (95% CI) P value‡
HOOS scores
HOOSPain§
  MoveTrain (n=22) 66.6±14.9 84.7±13.5 18.1±12.9 −2.75 (−8.66 to 3.16) 0.35
  Standard (n=20) 70.3±12.0 89.3±8.7 19.0±9.6
HOOSSymptoms§
  MoveTrain (n=22) 63.2±16.6 78.0±14.1 15.0±13.2 −5.55 (−13.10 to 1.99) 0.14
  Standard (n=20) 68.8±15.5 86.3±13.5 17.5±16.2
HOOSADL§
  MoveTrain (n=22) 79.5±15.0 92.0±11.2 12.5±11.0 −2.20 (−6.51 to 2.11) 0.32A
  Standard (n=20) 83.4±14.7 95.7±6.2 12.4±11.8
HOOSSport§
  MoveTrain (n=22) 58.5±20.0 83.0±16.4 24.4±18.1 −3.69 (−11.74 to 4.36) 0.36
  Standard (n=20) 69.1±17.6 90.6±11.2 21.6±15.6
HOOSQOL§
  MoveTrain (n=22) 55.1±14.8 68.2±16.8 13.1±13.8 −6.60 (−15.32 to 2.13) 0.13
  Standard (n=20) 52.2±15.2 73.1±15.3 20.9±16.6
PSFS, mean of up to five activities
PSFS¶
  MoveTrain (n=22) 5.8±1.9 7.5±2.2 1.7±1.7 −0.09 (−1.20 to 1.02) 0.87
  Standard (n=20) 5.3±1.5 7.2±2.2 1.8±1.8
PROMIS T- scores**
PROMIS mobility      
  MoveTrain (n=22) 50.0±5.7 53.5±6.1 3.5±4.8 −2.05 (−5.11 to 1.01) 0.18
  Standard (n=20) 47.9±6.2 54.3±5.9 6.4±5.8
PROMIS pain interference
  MoveTrain (n=22) 53.6±5.0 46.8±7.8 −6.8±6.3 −0.51 (−4.31 to 3.29) 0.79††
  Standard (n=20) 54.6±4.3 48.1±6.7 −6.5±6.6
PROMIS pain behaviour
  MoveTrain (n=22) 55.1±3.2 46.6±9.0 −8.4±7.5 −0.47 (−5.24 to 4.30) 0.85††
  Standard (n=20) 55.2±2.7 47.3±8.4 −7.9±8.5
PROMIS global physical health
  MoveTrain (n=22) 49.7±6.1 56.1±7.4 6.4±5.4 0.11 (−3.07 to 3.29) 0.95††
  Standard (n=20) 49.9±5.7 56.2±6.4 6.2±5.7
PROMIS global mental health
  MoveTrain (n=22) 52.3±9.4 53.8±11.2 1.5±5.6 −1.82 (−5.47 to 1.83) 0.32
  Standard (n=20) 55.5±7.9 58.7±8.5 3.2±5.7
Pain numeric rating scales
Pain (average)‡‡
  MoveTrain (n=22) 4.1±2.0 1.3±1.5 −2.9±1.5 0.21 (−0.96 to 1.38) 0.73§§
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Mean (95% CI) P value‡
Pain (worst)‡‡
  MoveTrain (n=22) 5.6±2.0 2.0±1.7 −3.7±1.8 0.36 (−0.74 to 1.46) 0.52§§
  Standard (n=20) 5.8±1.9 1.9±2.2 −3.9±3.0
*Change is calculated by subtracting the pretest value from the post- test value.
†The adjusted treatment effect from least squares means is calculated by subtracting the MoveTrain minus 
Standard at post- test and assesses the between- group difference in post- test values after adjusting for 
pretest.
‡Unless otherwise indicated, p value by analysis of covariance using a generalised linear model.
§Patient- reported outcome measures with 100=no disability.
¶Patient Specific Functional Scale (PSFS) assesses the level of difficulty performing up to five activities due 
to hip pain or symptoms. 0=unable to perform activity; 10=able to perform activity at preinjury level.
**PROMIS T- scores for the measures included in this study range from 20 to 80 and have a mean score of 
50 and SD of 10, using the US general population as the reference. A higher score represents more of the 
concept being measured. Minimally important differences (MIDs) have not been established for those with 
HRGP. More information regarding PROMIS score interpretation may be found at the following website: 
http://www.healthmeasures.net/score-and-interpret/interpret-scores/promis
††P value by non- parametric analysis of covariance.
‡‡Pain rated by patients using a verbal numerical pain rating scale. 0=no pain; 10=worst pain imaginable.
§§P value by analysis of covariance using multinomial generalised estimating equations with a cumulative 
logit.
HOOS, Hip Disability and Osteoarthritis Outcome Score; HOOSADL, function in activities of daily living; 
HOOSQOL, quality of life; HOOSSport, function in sports and recreation; HRGP, hip- related groin pain; 
MoveTrain, movement pattern training group; PROMIS, Patient- Reported Outcomes Measurement 
Information System.
Table 4 Continued
similar treatment effects and assist in improving HEP 
adherence.
We have developed methods to establish and monitor 
treatment fidelity. In the future, we will use the check-
list used for role- played scenarios to monitor actual 
treatment sessions. For chart reviews, we noted the two 
items most often scored as insufficient included ‘review 
of key concepts’ and ‘addressing barriers to HEP comple-
tion’. Discussion with treating PTs indicated they indeed 
performed these tasks; however, they did not specifically 
document their strategies. In the future, we will modify 
treating PTs’ documentation forms to provide a specific 
place to document these two key items. This addition will 
serve as an improved method to ensure documentation 
of protocol adherence and as a reminder to treating PTs 
to perform these items.
Preliminary effectiveness
Our study was designed to assess feasibility; therefore, we 
did not expect to find statistical differences in secondary 
outcome measures. Both groups demonstrated similar 
improvements in all patient- reported outcomes. These 
findings are important because it suggests that patients 
with HRGP may benefit from PT- led intervention. 
Patients in this study reported moderate activity limita-
tions at baseline. After treatment, HOOS subscales were 
substantially improved with increases of 12–24 points. No 
unexpected adverse events occurred, suggesting these 
interventions are safe.
After treatment, MoveTrain did demonstrate a signifi-
cantly larger reduction in hip adduction and pelvic 
drop during single leg squat compared with Standard, 
supporting our a priori hypothesis. The goal of Move-
Train training is to improve lower extremity kinematics 
during daily and patient- specific tasks. Because Move-
Train changes the way people move, stresses on joint 
tissues may be altered, potentially resulting in greater 
long- term effects than Standard. Interestingly, fewer 
patients in MoveTrain reported discomfort with their 
exercises (table 3). We are currently collecting patient- 
reported outcome measures 6 and 12 months after 
treatment to determine if between- group differences 
emerge over time. Further investigation is warranted to 
determine if the improved movement patterns can be 
sustained over time and have a protective influence on 
the hip.
There were similar strength improvements, ranging 
from 6% to 16%, in both patient groups. Although the 
MoveTrain group did not perform traditional strength-
ening exercises, the functional tasks performed 
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Mean (95% CI) P value‡
Hip kinematics for the study side (°)§    
Hip adduction angle¶
  MoveTrain (n=22) 23.5±11.4 15.6±9.5 −7.9±12.5 −7.2 (−12.9 to −1.4) 0.016
  Standard (n=20) 16.9±11.0 19.4±11.3 2.5±7.1
Pelvic tilt excursion**
  MoveTrain (n=22) −10.7±5.1 −7.5±4.6 3.3±5.7 3.0 (0.4 to 5.6) 0.026
  Standard (n=20) −8.6±7.2 −9.5±5.4 −0.8±4.6
  Trunk lean excursion**
  MoveTrain (n=22) 3.8±6.6 2.8±3.9 −1.0±6.3 −1.1 (−3.6 to 1.4) 0.37
  Standard (n=20) 7.5±8.9 5.3±5.6 −2.2±6.3
Hip muscle strength for the study side††
ABDs, torque (Nm)
  MoveTrain (n=22) 7.3±3.3 8.4±3.1 1.2±2.1 0.3 (−0.9 to 1.5) 0.65
  Standard (n=20) 6.8±3.6 7.8±2.9 1.0±2.3
ERs90° torque (Nm)
  MoveTrain (n=22) 2.3±1.0 2.5±0.9 0.2±0.8 −0.2 (−0.6 to 0.3) 0.44
  Standard (n=20) 2.3±1.1 2.7±1.1 0.4±0.7
  IRs90° torque (Nm)
  MoveTrain (n=22) 2.5±0.8 2.8±0.8 0.2±0.7 −0.1 (−0.6 to 0.5) 0.73
  Standard (n=20) 2.3±0.9 2.7±1.2 0.4±1.1
ADDs, torque (Nm)
  MoveTrain (n=21) 4.4±2.0 5.3±2.4 0.9±1.3 0.2 (−0.6 to 1.1) 0.60‡‡
  Standard (n=20) 4.7±3.1 5.2±2.1 0.5±1.9
Flexs, torque (Nm)
  MoveTrain (n=22) 5.8±2.1 7.0±2.6 1.3±2.1 0.6 (−0.6 to 1.7) 0.34
  Standard (n=19) 5.5±1.8 6.3±1.9 0.8±1.6
Exts, torque (Nm)
  MoveTrain (n=22) 8.8±4.0 9.4±4.0 0.5±2.7 −0.5 (−2.1 to 1.0) 0.51
  Standard (n=19) 8.9±4.4 9.9±4.4 1.0±2.3
*Change is calculated by subtracting the pretest value from the post- test value.
†The adjusted treatment effect from least squares mean is calculated by subtracting the MoveTrain minus Standard at post- test, and 
assesses the between- group difference in post- test values after adjusting for pretest.
‡Unless otherwise indicated, p value by analysis of covariance using a generalised linear model.
§Kinematics represent the mean of up to three trials where the sign of the measurements (ie, negative or positive) are included when 
computing the average.
¶Hip adduction angle was measures at the lowest depth of the single leg squat. Larger positive values indicate a larger hip adduction 
angle.
**Values for excursion were calculated from first initiation of descent to the end of descent on the stance leg. Pelvic tilt excursion: larger 
negative values indicate a larger pelvic drop. Trunk lean: larger positive values indicate trunk lean towards the weightbearing limb.
††Muscle torque (Nm) was normalised by body weight (N) × height (m) × 100 using the mean of up to three trials.
‡‡P value by non- parametric analysis of covariance.
ABDs, abductors with the hip in 0° hip flexion, 0° abduction and 0° rotation; ADDs, adductors with the hip in 0° hip flexion, 0° abduction 
and 0° rotation; ERs90°, external rotator strength with hip in 90° flexion, 0° abduction and 0° rotation; Exts, extensors with the hip in 0° 
hip flexion, 0° abduction and 0° rotation; Flexs, flexors with the hip in 0° hip flexion, 0° abduction and 0° rotation; IRs90°, internal rotator 
strength with hip in 90° flexion, 0° abduction and 0° rotation; MoveTrain, movement pattern training group.
training. Based on patient performance, the tasks were 
progressed by level of difficulty or by increasing resis-
tance. Therefore, these progressive activities may have 
contributed to improved muscle strength.
limitations
We cannot make definitive statements regarding efficacy 
of MoveTrain or Standard treatment; however, our results 
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treatment groups, and those in MoveTrain improved 
their kinematics. We did not have a control group; there-
fore, patient improvement may be related to passage of 
time. We consider this unlikely, because in our proof- 
of- concept study,9 patients with HRGP randomised to a 
6- week waitlist demonstrated a worsening in HOOSADL 
and no improvement in other HOOS subscales compared 
with baseline. Additionally, our patients reported pain 
duration greater than 3 months prior to enrolling, 
suggesting that time alone may not explain our results. 
We must acknowledge that we have completed a number 
of statistical tests, therefore increasing the likelihood 
of a type I error. We identified our a priori variables of 
interest and focused our discussion on results related 
to these variables. However, given limited information 
related to non- operative management of HRGP, we 
believe it important to report all analyses that may be 
useful for future investigations. Finally, we did not estab-
lish test–retest reliability of the strength measures used in 
this pilot study; however, we will include reliability testing 
for the future trial.
We completed a pilot, multicentre RCT to assess our 
capability of completing a larger, definitive RCT to 
assess the efficacy of MoveTrain. We encountered no 
major problems and have determined a full study can 
proceed with modifications. Preliminary results from 
this study suggests that both MoveTrain and Standard 
may result in improved patient- reported outcomes; 
however, only MoveTrain resulted in improved lower 
extremity kinematics. Additionally, fewer patients 
reported discomfort with the exercises provided in 
MoveTrain, which may influence patient adherence 
to treatment. Further investigation of MoveTrain is 
warranted. We do not know if the improvements in 
patient- reported outcomes observed in this study were 
due to the treatment provided or due to the fact that 
the participants interacted with a healthcare profes-
sional. An adequately powered RCT is needed to assess 
the efficacy of MoveTrain compared with an attention 
control. Future work will also include the assessment of 
the sustained benefits of PT- led interventions.
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